Key Drivers
- Strong Margins
- Cash Conversion
- Low Leverage
AIAI Summary
WST's evolution into a high-margin biologics and GLP-1 delivery beneficiary supports durable premium growth, but at ~44x earnings investors should wait for sustained cash conversion and post-cyber growth/margin execution before adding aggressively.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Cash Conversion
- •Low Leverage
WST remains fundamentally strong with high profitability, low leverage, and ample liquidity, but weaker quarterly cash conversion and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Strong rebound
- •Stretched momentum
WST is in a modest short-term uptrend above key averages, but with RSI near 72, consider taking caution near $365–$367 resistance while watching $355–$356 support.
Sharp 7.5% rebound from $336.94 since
Sentiment & News
Key News Insights:
- •Moderate Buy
- •Institutional Accumulation
- •Near-Term Headwinds
West Pharmaceutical Services has strong analyst and institutional support, though near-term headwinds and selective selling warrant monitoring.
The news is broadly supportive for West's outlook, reinforcing a positive long-term investment case
Similar Companies in Healthcare
Other companies in the same sector with AI ratings